SeaStar Medical Holding (ICU) said Monday that the US Food and Drug Administration has approved its investigational device exemption application, allowing the conduct of a study to evaluate the safety and initial efficacy of its selective cytopheretic device, or SCD-Adult, in cardiorenal syndrome.
The device will be evaluated in adults with acute heart failure and worsening renal function or severe right ventricular failure awaiting left ventricular assist device implantation, according to SeaStar Medical.
The study is expected to include 20 patients at up to five clinical sites and is funded by a $3.6 million grant from the National Institutes of Health, SeaStar said.
Shares of the company were 3% lower in early trading Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.